140P Preliminary results from PROPEL: A phase I/II study of bempegaldesleukin (BEMPEG: NKTR-214) plus pembrolizumab (PEMBRO) with or without chemotherapy in patients with metastatic NSCLC

Autor:	E. Felip, D.R. Spigel, O.J. Juan Vidal, J.T. Beck, C. Aguado de la Rosa, D.H. Johnson, E. Spath-Schwalbe, A. Reinacher-Schick, D. Rodriguez Abreu, M. Altan, N. Reinmuth, M.J. Edelman, M. Reck, Q. Zhao, S. Banerjee, S. Chaudhry, D. Chien, M.A. Tagliaferri, J. Zalevsky, A. Ganti
Rok vydání:	2021
Předmět:	Oncology Hematology
Zdroj:	Annals of Oncology. 32:S1438-S1440
ISSN:	0923-7534
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::72e0421c1f016a2115b02466d64a7163 https://doi.org/10.1016/j.annonc.2021.10.159 Zobrazit plný text záznamu